420
Participants
Start Date
May 20, 2021
Primary Completion Date
August 25, 2021
Study Completion Date
January 28, 2022
MVC-COV1901 (High-Dose)
Approximately 300 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) and Visit 4 (Day 29) via intramuscular (IM) injection in the deltoid region
MVC-COV1901(Mid-Dose)
Approximately 100 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) and Visit 4 (Day 29) via intramuscular (IM) injection in the deltoid region
Hualien Tzu Chi Hospital, Hualien City
Shuang H Hospital, New Taipei City
National Taiwan University Hospital, Taipei
Chang Gung Medical Hospital Linkou, Taoyuan District
Lead Sponsor
Medigen Vaccine Biologics Corp.
INDUSTRY